Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2Active not recruiting 2Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Anus Neoplasms 2Rectal Neoplasms 1HIV Infections 1Anal Canal Carcinoma 1

Interventions

pembrolizumab 382Carboplatin 280Specimen Handling 266Nivolumab 256Magnetic Resonance Spectroscopy 247Cyclophosphamide 243Cisplatin 215Paclitaxel 209Radiotherapy 194Biopsy 171Gemcitabine 156Dexamethasone 149durvalumab 148atezolizumab 127Rituximab 122Doxorubicin 119Bevacizumab 115Ipilimumab 114Lenalidomide 112Radiation 111Pemetrexed 104Docetaxel 104Etoposide 103venetoclax 98fludarabine 97Capecitabine 94Radiosurgery 93Fluorouracil 93Prednisone 90Oxaliplatin 90

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Proctoscopy × 1 year × Clear all
NCT03233711 2026-05-29

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡